tradingkey.logo
搜尋

Castle Biosciences Inc

CSTL
添加自選
24.110USD
-0.600-2.43%
收盤 07/02, 13:00美東報價延遲15分鐘
730.44M總市值
虧損本益比TTM

Castle Biosciences Inc

24.110
-0.600-2.43%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.43%

5天

+5.24%

1月

+22.32%

6月

-37.44%

今年開始到現在

-38.02%

1年

+20.49%

關鍵數據
24.710今開
24.980最高
175.50K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.58%換手率
24.710昨收
24.020最低
3.32M成交額
40.03本益比靜
1.58市淨率
0.00%股息率 TTM
-2.45%ROA
44.28052週最高
0.70量比
18.25M淨利潤
30.30M總股本
-0.4158每股盈餘TTM
1.07Beta
-2.85%ROE
14.59052週最低
3.89%振幅
72.80%毛利率
730.44M總市值
6.81回報/風險
3.11%風險率

TradingKey Castle Biosciences Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Castle Biosciences Inc當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名15/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為強力買入。最高目標價為43.56。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Castle Biosciences Inc評分

相關信息

行業排名
15 / 204
全市場排名
65 / 4565
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Castle Biosciences Inc亮點

亮點風險
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
業績高增長
公司營業收入穩步增長,連續3年增長56.62%
業績轉虧
公司業績轉虧,最新年度虧損美元
估值合理
公司最新PE估值-57.98,處於3年歷史合理位
機構減倉
最新機構持股27.62M股,環比減少6.13%

分析師目標

基於 9 分析師
強力買入
評級
43.556
目標均價
+79.09%
漲幅空間

Castle Biosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Castle Biosciences Inc簡介

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
公司代碼CSTL
公司Castle Biosciences Inc
CEOMaetzold (Derek J)
網址https://castlebiosciences.com/

常見問題

Castle Biosciences Inc(CSTL)的當前股價是多少?

Castle Biosciences Inc(CSTL)的當前股價是 24.11。

Castle Biosciences Inc 的股票代碼是什麼?

Castle Biosciences Inc的股票代碼是CSTL。

Castle Biosciences Inc股票的52週最高點是多少?

Castle Biosciences Inc股票的52週最高點是44.28。

Castle Biosciences Inc股票的52週最低點是多少?

Castle Biosciences Inc股票的52週最低點是14.59。

Castle Biosciences Inc的市值是多少?

Castle Biosciences Inc的市值是730.44M。

現在Castle Biosciences Inc(CSTL)的股票是買入、持有還是賣出?

根據分析師評級,Castle Biosciences Inc(CSTL)的總體評級為STRONG BUY,目標價格為43.56。

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是多少

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是-0.83。